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Abstract: Leishmaniasis is a neglected disease that is caused by different species of the protozoan
parasite Leishmania, and it currently affects 12 million people worldwide. The antileishmanial
therapeutic arsenal remains very limited in number and efficacy, and there is no vaccine for this
parasitic disease. One pathway that has been genetically validated as an antileishmanial drug target
is the biosynthesis of uridine diphosphate-glucose (UDP-Glc), and its direct derivative UDP-galactose
(UDP-Gal). De novo biosynthesis of these two nucleotide sugars is controlled by the specific
UDP-glucose pyrophosphorylase (UGP). Leishmania parasites additionally express a UDP-sugar
pyrophosphorylase (USP) responsible for monosaccharides salvage that is able to generate both
UDP-Gal and UDP-Glc. The inactivation of the two parasite pyrophosphorylases UGP and USP,
results in parasite death. The present study reports on the identification of structurally diverse
scaffolds for the development of USP inhibitors by fragment library screening. Based on this screening,
we selected a small set of commercially available compounds, and identified molecules that inhibit
both Leishmania major USP and UGP, with a half-maximal inhibitory concentration in the 100 µM
range. The inhibitors were predicted to bind at allosteric regulation sites, which were validated by
mutagenesis studies. This study sets the stage for the development of potent USP inhibitors.
Keywords: UDP-sugar pyrophosphorylase; allosteric inhibitor; inhibitor scaffold; library screen
1. Introduction
Leishmaniasis, categorized as a "Neglected Tropical Disease by WHO, affects about 12 million
people worldwide and is often related to poverty [1]. The causative agents of this disease are protozoan
flagellates of the genus Leishmania, and there are over 20 different species that are reported to cause
this disease in humans, as well as in various synanthropic animal hosts [2]. Depending on the infecting
Leishmania species and the immune status of the host, clinical manifestation can vary from disfiguring
cutaneous or mucocutaneous forms, to a life-threatening visceral form [3,4]. The mortality due to
visceral leishmaniasis has decreased from approximately 62,000 to 14,000 casualties between 2013 and
2016 [5,6]. However, leishmaniasis remains associated with high morbidity. As of now, no vaccines are
available against this disease [7]. Growing concern over reports of drug resistance and adverse effects
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due to the overuse of available drugs calls for the discovery of cost- and therapeutically effective,
parasite-specific lead compounds against this disease [8,9].
Leishmaniasis is spread through the bite of a female Phlebotomine sandfly, the insect vector of the
parasite. Within the intestinal tract of the insect vector, Leishmania exists as an extracellular flagellated
promastigote, whereas in mammalian hosts, it is predominantly found intracellularly in the macrophage
phagolysosomes as a flagellated amastigote [10]. In order to adapt to the changing environmental
conditions during its digenetic life cycle, Leishmania undergoes various morphological, physiological,
and biochemical changes. The most prominent one is the synthesis of a dense surface glycocalyx,
which contains various GPI-anchored molecules, including glycoproteins, lipophosphoglycans (LPGs),
proteophosphoglycans (PPGs), and abundant glycoinositolphospholipids (GIPLs). Leishmania also
secretes various glycoconjugates, especially proteophosphoglycans (PPGs) [11]. The secreted and surface
glycoconjugates of the promastigote play a role in survival, infectivity, or virulence but are dispensable
for Leishmania viability in culture [11,12].
For the biosynthesis of glycoconjugates, Leishmania parasites require an abundant supply of
nucleotide sugars. They synthesize uridine diphosphate-glucose (UDP-Glc), UDP-galactose (UDP-Gal),
UDP-N-acetylglucosamine (UDP-GlcNAc), UDP-galactofuranose (UDP-Galf ), GDP-mannose (GDP-Man),
and GDP-arabinose (GDP-Ara), of which UDP-Glc has the highest steady-state pool size [13].
In addition to its contribution towards glycocalyx biosynthesis, UDP-Glc is involved in base J
(β-D-glucosyl-hydroxymethyluracil) biosynthesis, an unusual DNA base that is found in Leishmania
parasites [14,15]. It is assumed that base J plays an important role in parasite growth since attempts to
delete JBP1, a gene encoding one of the two thymidine hydroxylases involved in the first step of base
J synthesis, were unsuccessful [15,16]. Base J occurs in telomeric repeats and at transcription initiation
and termination sites, and plays a role in transcription regulation [17]. Finally, UDP-Glc is the major
source for glucosylation of various glycoproteins in the endoplasmic reticulum mediated by the enzyme
UDP-glucose: glycoprotein glucosyltransferase (UGGT) which is known to be involved in the protein
folding machinery [18]. In the related parasite Trypanosoma brucei, UGGT is not essential for parasite growth
under standard culture conditions [19].
In prokaryotes and eukaryotes, the de novo synthesis of UDP-Glc is catalyzed by a specific
UDP-glucose pyrophosphorylase (UGP) from the substrates uridine triphosphate (UTP) and
glucose-1-phosphate (Glc-1P). UDP-Glc is then partially converted into UDP-Gal by the UDP-Glc
4′-epimerase [20]. In addition to this de novo pathway, Leishmania parasites and plants possess
a UDP-sugar pyrophosphorylase (USP), which has broad substrate specificity and is involved in
monosaccharide salvage [21–24]. In vitro, Leishmania and plant USPs preferentially use UTP as
a nucleotide donor, and can activate a variety of sugar-1-phosphate [21,25]. These enzymes are
most active with galactose-1-phosphate (Gal-1P) and Glc-1P, with a slight preference for the former,
but they cannot activate N-acetylated sugars [21,25]. In contrast, UGP is highly specific for Glc-1P.
UDP-sugar-producing pyrophosphorylases catalyze reversible reactions, require magnesium for
catalysis, and act through an ordered sequential Bi-Bi reaction mechanism. In the forward reaction,
UTP binds before the sugar-1P, and after catalysis, inorganic pyrophosphate (PPi) is released before
the UDP-sugar [21,26,27]. The crystal structures of Leishmania major USP [28] and UGPs from several
eukaryotic organisms have been elucidated [29–34] and they reveal a common tripartite structure with
a small N-terminal domain, a large central catalytic domain with a Rossmann-like fold, and a β-helix
C-terminal domain. An important difference between parasite (and plants) pyrophosphorylases and
human UGP lies in their oligomerization states. Both Leishmania UGP and USP are active in their
respective monomeric forms, whereas human UGP (hUGP) is an active octamer [21,26,35]. In the
monomeric enzymes, the stepwise binding of the substrates causes vast structural rearrangement,
leading first to the formation of the sugar-1P binding pocket, and then to intramolecular closure of the
active site. In contrast, the human enzyme uses an intermolecular mechanism, in which interactions
between the subunits stabilizes the sugar binding region [34].
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Deletion of the UGP-encoding gene in L. major strongly reduced, but did not abolish the biosynthesis
of UDP-Gal and its immediate precursor UDP-Glc, since USP enables the limited biosynthesis of both
nucleotide sugars [36]. Deletion of one of the two usp alleles in a UGP-deficient parasite strain (ugp−/−),
and conditional degradation of the enzyme produced by the remaining usp allele led to parasite growth
arrest and cell death. Thus, the biosynthesis of UDP-Gal and/or UDP-Glc is essential for L. major
survival [37]. Biosynthesis of UDP-Gal is also essential for the trypanosomatid parasites Trypanosoma
brucei [38,39] and Trypanosoma cruzi [40]. However, in these two parasites, the only pathway for UDP-Gal
biosynthesis is via UGP and the UDP-Glc 4′-epimerase. Although T. cruzi genomes encode a USP,
the hexose transporter of this parasite does not import galactose into the cell [41]. Thus potent and
specific inhibitors of the enzymes involved in UDP-Glc/UDP-Gal biosynthesis may represent novel
therapeutics to combat infections that are caused by trypanosomatid parasites.
Enzymes of the uridylyltransferase family across all species exhibit highly conserved active sites
at primary, secondary, and tertiary structural levels. Thereby, inhibitors targeting the catalytic sites
of the enzymes would likely show cross-reactivity and off-target effects. An approach to achieve
selective inhibition would employ allosteric regulation sites, which often have a unique composition
and conformational properties [42,43]. In previous work, murrayamine-I was identified as an allosteric
inhibitor of L. major UGP [42]. However, the suppression of the UDP-Glc/UDP-Gal biosynthesis in
Leishmania parasites would require the inhibition of both UGP and USP. In this study, we therefore
looked for specific inhibitors of Leishmania USP through a combination of biochemical and computational
approaches, and demonstrated the possibility of developing a compound that is able to selectively inhibit
both Leishmania USP and UGP.
2. Results
2.1. Identification of Scaffolds for Inhibitor Development by Small-Molecule Fragment Screening
To identify scaffolds for the development of Leishmania USP inhibitors, a chemical library of 965
fragment molecules from the University of Dundee Drug Discovery Unit (DDU) was screened with
bio-layer interferometry (BLI) using an Octet Red 384 platform. The principle and performance of this
technique have been described elsewhere [44,45].
LmUSP was expressed in bacteria with an N-terminal biotin acceptor peptide (BAP epitope),
purified, and subsequently biotinylated by incubation with the biotin ligase BirA. Immobilization
of biotinylated LmUSP to Super Streptavidin (SSA) biosensors was then assessed. Upon assessment
by biolayer interferometry, LmUSP showed a measured wavelength shift of ~4 nm, with a loading
enzyme concentration of 12.5 µg/mL. A natural ligand of LmUSP, UTP, was used as the positive
control to test for binding. A set of eight SSA biosensors were loaded with a 12.5 µg/mL solution of
biotinylated LmUSP, and immersed in UTP solutions of various concentrations, ranging from 1.3 µM
to 1 mM. Despite the sub-optimal immobilization level of LmUSP on the SSA biosensors, UTP bound
in a dose-dependent manner (Figure 1). In this experiment, the estimated equilibrium dissociation
constant (KD) for UTP was 89 µM, which correlates well with the Km value of 100 µM reported
previously [21].
The small molecule fragments library was then screened against LmUSP to define the binding
profile of each fragment. Compounds were initially tested at a concentration of 200 µM, and excess
UTP (200 µM) was added to the running buffer in order to keep the enzyme in its physiological UTP
bound state. Fragments with a response level greater than 0.05005 (corresponding to a median response
of 0.0082 + 3x robust standard deviation of 0.01395) were considered as hits (Figure 2). Based on this
equation, 96 fragments, reflecting a primary hit rate of 9.9%, were selected for a follow-up study.
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Figure 2. Responses for the bio-layer interferometry screen with LmUSP. The binding curve of all
fragments was analyzed with ForteBio software and plotted as compounds (X-axis) versus response.
Fragments with a response > 0.05005, highlighted in red, were selected for a second screen.
The primary hits were further confirmed by a second screen with a 7-point concentration series
from 2 µM to 500 µM. In this validation experiment, 57 fragments showed stoichiometric binding to
the target, with approximate binding constants KD ranging from ~60 µM to 480 µM (Supplementary
Tabl S1). Table 1 shows th four fra me ts that bind to LmUSP with an estimated KD value of less than
100 µM. Typically, fragment molecules have a low affinity for the enzyme (KD ≥ 100 µM), but most of
the atoms participate directly in the binding process [46]. These fragment molecules can thus provide
valuable scaffolds for inhibitor development.
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Table 1. Chemical structure, binding response, and binding affinity of the top four fragment hits from
a dose-response binding study with LmUSP.
Fragment Structure Primary Binding Response Estimated KD (µM)
DDD00095351
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To validate the identified scaffolds, we chose fragment DD00808259, which showed the highest
degree of binding in the pri ary screen, and a low KD value of 67.6 µM, and searched for commercially
available co pounds containing similar chemical epitopes. Eleven compounds were selected from
a structural similarity search with this fragment against the commercially available ChemBridge
screening compound database (Supplementary Figure S1). These compounds followed the Lipinski’s
rule of five (MW < 500 Da; ClogP < 5; H-bond donors < 5; H-bond acceptors < 10). Their ability to
inhibit LmUSP in vitro activity was tested by using 500 µM compounds with a final dimethyl sulfoxide
(DMSO) concentration of 10 . Compounds #4 and #8 (Figure 3A) inhibited UDP-Gal production
by at least 80% compared to the DMSO control, which was set to 100% (Figure 3B) whereas the
other compounds only moderately inhibited LmUSP (less than 30 inhibition). Moreover, at 500 µM,
compounds #4 and #8 inhibited more than 95% of LmUGP activity (Figure 3B). In contrast, the activity
of hUGP was decreased by less than 20% (Figure 3B). The compounds thus show selectivity towards
the parasite pyrophosphorylases.
Five commercially available analogs of compound #8 were subsequently tested for activity against
LmUSP, LmUGP, and hUGP, at an initial concentration of 500 µM. The compounds, named #8A to #8E
(Figure 4A), showed more than 85% reduction of LmUSP and LmUGP in vitro activity (Figure 4B).
At this high concentration, compounds #8B, #8D and #8E also showed a clear inhibition of hUGP
(Figure 4B).
The compounds #4, #8 and #8A to #8E were subsequently used in dose-response studies to
measure the corresponding IC50 (inhibitor concentration yielding 50% inhibition) values against
Leishmania USP and UGP. The IC50 values based on sigmoidal dose-response curves (presented in
Supplementary Figures S2 and S3) are summarized in Table 2.
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Table 2. IC50 values of compounds against Leishmania USP and UGP at 95% confidence intervals.
Compounds were tested at several concentrations from 7 µM to 500 µM.
Compounds IC50 (µM)
LmUSP (UDP-Gal) LmUGP (UDP-Glc)
#4 135.00–175.00 126.30–134.00
#8 78.06–106.60 119.80–151.20
#8A >250 >250
#8B 47.17–66.43 55.06–69.13
#8C >250 >250
#8D 169.80–194.80 192.70–242.10
#8E 40.39–46.29 37.99–46.76
Compound #8 was found to have a slightly higher potency toward LmUSP than #4. Substitution
of the indole ring carbon 6 in #8 by chlorine or a methoxy group resulted in compound #8B and #8C
respectively (Figure 4A). Interestingly, the chlorine substituent increased the inhibitory activity towards
both parasite pyrophosphorylases, whereas the more bulky methoxy group decreased it. Similarly,
the presence of a methyl group in #8A compared to #8 decreased the potency of the compound. Finally,
compounds #8D and #8E resemble #8, but they present a different orientation of the quinazolinone
group, and differ from each other by the presence of a chlorine or fluorine substituent at the C6
indole group. Compound #8E was identified as the best inhibitor of the parasite pyrophosphorylases,
with an IC50 value of below 50 µM, for both LmUSP and LmUGP.
2.3. Predictions of the Compounds’ Binding Sites on LmUGP and LmUSP
Computational docking was used to predict the favored binding sites for compounds #4 and #8
on LmUGP and LmUSP (Figure 5) using AutoDock software. Both compounds were predicted to bind
to LmUGP at an allosteric site that was previously shown to be functionally relevant (Figure 5A) [42].
Inhibitor binding in this area is expected to impede the closing of the LmUGP catalytic pocket, which
is necessary for an efficient enzymatic reaction [42,47].
Docking to LmUSP suggested that compound #4 preferentially binds to one site, here named
site 1, located in the proximity of the active center of the enzyme (Poses 1, 2, 3, and 4). This site is also
predicted to be the preferred binding site of compound #8 (Poses 1 and 2), but this last compound may
also bind to site 2 (Pose 3 & 4) (Figure 5B). Table 3 shows the binding energy corresponding to the four
preferred orientations of each compound to LmUSP.
Docking of compounds #4 and #8, along with other identified inhibitors (#8B, #8D, and #8E) was
repeated with Schrödinger Maestro software. The docking results confirmed the binding sites for
compounds #4 and #8. The top binding site of inhibitors #8B, #8D, and #8E was at the same allosteric
site of LmUGP and site 1 of LmUSP (Supplementary Figures S4 and S5).
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Table 3. Calculated ∆G binding energy values (kcal/mol) for the preferred binding orientations of
compound #4 and #8 to LmUGP and LmUSP proteins.
Ligand Pose Compound #4 Binding Energy (kcal/mol) Compound #8 Binding Energy (kcal/mol)
LmUGP LmUSP LmUSP
Pose 1 −7.61 −7.83 7.92 −8.22
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2.4. Binding Site Validation thr ugh Site-Directed Mutagenesis
To analyze if the predicted binding sites have any functional relevance concerning the LmUSP
activity, site-directed mutation studies were performed. Initially, valine 330 and valine 199, located
at sites 1 and 2 respectively, were mutated to a tryptophan residue to introduce steric hindrance,
which might block the structural transition associated with protein catalysis. As seen in Table 4, these
mutations considerably decreased the affinity of LmUSP for its substrate Gal-1P (higher Km) and led
to lower catalytic efficiencies. Since the V330W mutation resulted in a higher Vmax, we hypothesized
that the pi-interaction between the introduced tryptophan 330 and phenylalanine 383 (Supplementary
Figure S6) might be responsible for a conformation favoring catalysis. We thus mutated F383 to
arginine, and also generated an LmUSP mutant carrying both the V330W and F383R mutations. Both
the single mutation F383R and double mutationV330W/F383R strongly reduced the overall catalytic
efficiency of the enzyme. These results demonstrate that site 1 and 2, although they are remote from
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the active center, are connected to the catalytic activity of LmUSP, and sterically blocking these sites
inhibits the enzyme. Site 1 and 2 can therefore be considered as potential allosteric inhibitory sites.
Table 4. Kinetic parameters for Gal-1P with wild-type LmUSP and various mutants. The efficiency
obtained for the wild-type protein was set to 100%. Errors are given as standard deviations from
a single experiment with duplicates.
LmUSP Vmax(µmol min−1 mg−1) Km (µM) Gal-1P kcat (s
−1) kcat/Km(µM−1 s−1)
% Catalytic
Efficiency
Wild type 184.4 ± 6.36 529.20 ± 24.60 216.45 ± 7.47 0.409 ± 0.03 100 ± 8.094
V330W 271.70 ± 19.37 1255.00 ± 145.66 319.32 ± 22.77 0.255 ± 0.01 62.25 ± 2.79
F383R 14.77 ± 0.24 364.00 ± 22.20 17.33 ± 0.28 0.047 ± 0.002 11.64 ± 0.52
V330W/F383R 21.76 ± 1.26 276.45 ± 51.26 25.58 ± 1.48 0.093 ± 0.01 22.85 ± 2.92
V199W 76.79 ±2.94 1007.25 ± 18.03 90.25 ± 3.46 0.089 ± 0.001 21.86 ± 0.44
3. Discussion
The available treatment options for leishmaniasis are limited to pentavalent antimonials,
amphotericin B, miltefosine, paromomycin, sitamaquine, pentamidine, or a combination of these drugs
when resistance is reported. Except for sitamaquine, these are wide-spectrum drugs that were not
originally developed for treating leishmaniasis [8]. To date, there is no vaccine against leishmaniasis.
Biosynthesis of UDP-Glc and/or UDP-Gal by Leishmania promastigotes is essential for parasite
growth and survival in vitro [37]. The two enzymes, UGP and USP, found in all Leishmania species,
are essential for the production of these activated sugars. They contribute to the synthesis of the
parasite glycocalyx, and an unusual DNA base J that is likely involved in parasite growth and
transcription regulation [17]. Since USP complements the activity of UGP, it would be pivotal to inhibit
both enzymes for a clinical outcome. Moreover, the active sites of the human enzyme hUGP and
parasite pyrophosphorylases show common structural details, so that potential cross-reactivity has to
be considered during inhibitor design. We have previously described the detailed enzymatic cycle of
LmUGP and we highlighted important structural and mechanistic differences between Leishmania and
human UGP [34,35,47]. Like LmUSP, LmUGP is an active monomer that undergoes large structural
changes during its enzymatic cycle. Binding of UTP to the enzyme leads to the formation of the
glucose-1-phosphate binding pocket. Binding of this second substrate triggers further conformational
changes that stabilize the substrates, and “lock” the enzyme in a compact form that is optimal for
the catalytic reaction [47]. In contrast, hUGP is active as an octamer, and it uses an intermolecular
lock mechanism involving inter-subunit contacts, and it is associated with more restricted molecular
movement [34,35]. These mechanistic differences might be exploited to develop selective inhibitors
of the parasite enzymes as, recently demonstrated by the identification of an allosteric inhibitor that
selectively affects LmUGP [42].
Several other studies have aimed at identifying specific inhibitors of pyrophosphorylases to
selectively target trypanosomatid parasites. In particular, inhibitors of Leishmania GDP-mannose
pyrophosphorylase and T. brucei UDP-N-acetylglucosamine pyrophosphorylase, two genetically
validated targets, have been reported, and they display selectivity over their human orthologues [48–50].
Some of these inhibitors show anti-parasite activity. Additionally, inhibitors of both UGP and USP
have been developed, to study the importance of UDP-sugars in plants (Figure 6) [24,25,51]. For this
purpose, the potential inhibition of human UGP was not a concern, and it was thus not tested. Since the
compounds inhibited both UGP and USP, the authors have suggested that they target the active site of
the enzymes. With the aim of identifying inhibitors that are selective over human UGP, we performed
a small molecule fragment screen with Leishmania major USP as a target. This screen identified 57 small
molecules binding to LmUSP, with an estimated KD ranging from ~ 60 µM to 480 µM. Because of their
small sizes, the potency of such molecules is rather low, but most of the atoms contribute directly to
the binding process [46]. The identified fragments are dissimilar from the substrates of the enzyme,
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and are thus valuable scaffolds for the development of allosteric inhibitors. To validate the result of
this screen, we purchased commercially available compounds containing epitopes that are identical or
similar to the most potent fragment, and tested for inhibitory activity against LmUSP in vitro. Two of
the 11 compounds initially chosen showed clear inhibition of LmUSP activity with IC50 in the 100 µM
range (compounds #4 and #8). Remarkably, these two compounds also inhibit LmUGP activity, but they
have little effect on the human enzyme. Five derivatives of compound #8 were also analyzed, and this
led to the identification of an inhibitor of both parasite pyrophosphorylases, with IC50 values < 50 µM
(compound #8E). These analogs of compound #8 are also selective for the parasite enzymes, but a modest
inhibition of hUGP is observed at high compound concentration. The inhibitors identified in this study
differ from the previously described inhibitors of USP (Figure 6). They include a quinazolinone, as the
fragment selected from the library screen, and an indole group.
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Computational methods were used to explore possible binding modes f the inhibitors to LmUGP
and LmUSP. Interestingly, the preferred predicted binding site of the inhibitors to LmUGP was the
previously rep rted allosteric site [42]. In the case of LmUSP, two different cavities locat d utsi e,
but in the proximity of the cataly ic site, were id ntified as preferential binding sites of the inhibitors.
Point mutations of residues present at th sites r ulted in a drastic reduc ion of LmUSP catalytic
efficiency, demo strating the potential for argeting these cavities for llosteric regulation. The bound
compounds might be inh biting Leishmania nzymes by hindering the structural transi io that is
associated with enzymatic activity [47]. Unfortunately, because of the li ite l ility of the
identified inhibitors, we did not s ccee i tai i a cr stal structure of LmUSP or LmUGP with
the bound inhibitors. Such structures could shed light on the exact binding modes and epitopes that
are making contact with protein residues to assist ligand opti ization, for improved binding and
selective inhibition. Chemical derivatization of the compounds, and structure–activity relationship
(SAR) studies might improve their properties with regard to solubility, binding affinity, and specificity.
In conclusion, this study describes the identification of first-generation inhibitors of Leishmania
major USP and UGP, based on small-molecule fragment library screening. The identified inhibitors were
predicted to bind to allosteric pockets of LmUSP and LmUGP that have been validated by mutagenesis
experiments, and they display some specificity over human UGP. These compounds that follow the
Lipinski’s rule of five, as well as the structurally diverse molecular scaffolds that were identified in the
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library screening, are promising starting points for the development of potent and selective inhibitors
of Leishmania major USP.
4. Materials and Methods
4.1. A BLI Screen Using Recombinant LmUSP
A vector containing the His(6)-biotin acceptor peptide (BAP) tag was kindly provided by Prof.
Mike Ferguson from the University of Dundee. The BAP tag was inserted in the XbaI and NdeI
restrictions site of the previously described pET22b-LmUSP [21]. The plasmid with insert was then
transformed into the E. coli BL21(DE3) expression strain, and LmUSP was expressed and purified,
as described previously [21]. Exactly 2 mg of TEV protease was added to cleave off the His tag.
The protein was dialyzed in 3 × 1 L Buffer C (50 mM TRIS pH 8.0, 150 mM NaCl, 10 mM MgCl2).
A concentration of 100 µM D-Biotin, 500 µM ATP, and 200 µM BirA enzyme were added to the protein
and incubated for 18 hr for biotinylation. The sample was concentrated to 11 mL, using a Vivaspin
20 30 kDa PES centrifugal concentrator (Sartorious, Stonehouse, United Kingdom). The protein was
loaded onto a Superdex 200 XK26/60 equilibrated with Buffer C on the AKTA Pure at 4 ◦C. The eluted
monomeric protein was then concentrated to 0.98 mg/mL using a Vivaspin 20 30 kDa PES centrifugal
concentrator, and used for loading onto super streptavidin (SSA) biosensors (Fortebio, Shanghai, China,
Part No. 18-5057, Lot No. 1612162).
The loading response to SSA biosensors was measured to find the optimal protein concentration
to be used for the screen. Briefly, biosensor tips were hydrated in assay buffer (50 mM Tris pH 8.0,
150 mM NaCl, 10 mM MgCl2) for a minimum of 5 min before being sequentially transferred to assay
wells containing 1) assay buffer (60 s) to establish the baseline, 2) protein at 12.5, 25, or 50 µg/mL
(900 s) to measure protein loading, and 3) assay buffer to assess the reversibility of protein binding
to the sensor. The concentration that was optimal for screening was identified to be 12.5 µg/mL.
A concentration-effect curve for UTP (1.4 µM to 1 mM) was carried out, using SSA sensors with
12.5 µg/mL immobilized LmUSP, to derive an affinity estimate (Kd).
For fragment screening, 16 SSA biosensors were prepared by loading LmUSP (12.5 µg/mL) for
900 s; free streptavidin sites were then blocked with biocytin (10 µg/mL) for 120 s, and finally washed
in buffer W (50 mM Tris pH 8.0, 150 mM NaCl, 10 mM MgCl2, 200 µM UTP) for 60 s. In parallel,
another 16 SSA sensors were loaded with 10 µg/mL biocytin alone, which acts as a quenching agent to
block streptavidin sites on the sensor surface, and then washed with buffer W. These were used as
reference sensors.
Initial screening was performed with DDU fragment set (965 fragments) at a single point
concentration of 200 µM. The assay consisted of a 60 s baseline step, a 60 s association step, and
a 60 s dissociation step. The assay was repeated with the streptavidin blocked control biosensors.
Response levels for each compound were calculated by baseline subtraction, and the subtraction of
the reference responses from the LmUSP responses. From the initial putative hits, compounds were
further validated in a 7-point concentration series using 3-fold dilutions of each fragment ranging from
500 µM to 2.05 µM. Data were processed, and kinetic parameters were calculated, using the ForteBio
software. A visual inspection of curves alongside steady state fitting was used to identify fragments
of interest.
4.2. Fragment Similarity Search
The structure of the top fragment was drawn in the Ketcher platform of the ChemBridge
(ChemBridge Corporation, San Diego, CA, USA) chemical store website Hit2Lead (https://www.
hit2lead.com/) [52], and a similarity-based search was performed against the screening compounds
database. The search result was visually inspected to select 11 compounds with a similar chemical
epitope: #1 (CID 9245967), #2 (CID 9214059), #3 (CID 9252929), #4 (CID 9207718), #5 (CID 9231249),
#6 (CID 9270353), #7 (CID 9195974), #8 (CID 9206277), #9 (CID 9280745), #10 (CID 9329111) and #11
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(CID 9212920). These were purchased from the ChemBridge Hit2Lead store to test for inhibition
against LmUSP, LmUGP, and hUGP. Five structural analogues of the initial hit compound #8: #8A (CID
9219493), #8B (CID 9277739), #8C (CID 9214406), #8D (CID 9251350), and #8E (CID 9259570) were also
purchased and tested for inhibition. The compounds were dissolved in 100% DMSO, and stored in
glass vials at a concentration of 100 mM in the dark.
4.3. Protein Purification and Mutant Generation
LmUSP, LmUGP, and hUGP proteins were produced and purified as described
previously [21,26,35]. Q5 Site-Directed Mutagenesis Kit from New England BioLabs was used to
generate different LmUSP mutants. The primer pairs GGAGTACAACTGGTTTGCCGAGGTCTCGCGC
and ACGTTCGCGACCAGCCAC were used for the generation of the LmUSP V330W mutant,
GTGCCGGAGCGCATCAATCCCAAG and GATACCGTGCGACTCCCGCAG for the LmUSP F383R
mutant, and GCAGGGGCAGTGGTTCTGTTTTGC and TTGAGCACATGCAAGTTG for the LmUSP
V199W mutant. Mutations were confirmed by sequencing of the plasmids.
4.4. Enzyme Activity Assay and Dose Response Study
Compounds were tested at a concentration of 500 µM with 20 nM enzyme in an high-performance
liquid chromatography (HPLC)-based assay at a final reaction volume of 100 µL. The DMSO
concentration in the reaction was kept at 10%. The reaction buffer consisted of 10 mM Tris-HCl
pH 8.0, 2 mM MgCl2, 10 mM NaCl, 0.005 U of inorganic pyrophosphatase (Thermo Fisher Scientific,
Vilnius, Lithuania), and 1 mM Dithiothreitol (DTT) (for LmUSP and LmUGP only). Protein was
incubated with the inhibitors and UTP (final concentration of 0.8 mM in reaction) for 30 min at room
temperature, before the addition of the reaction buffer. The reaction was started with the addition
of Gal-1P for LmUSP and Glc-1P for LmUGP and hUGP (final reaction concentration of 2 mM) and
incubated for 30 min at 25 ◦C, before heat inactivation at 95 ◦C for 15 min. The samples were spun
down and the supernatants applied to a Dionex CarboPac™ PA10 column (Thermo Fisher Scientific,
Sunnyvale, CA, USA). UDP-Gal or UDP-Glc (products) were separated from UTP (substrate), UMP,
and UDP (both, UTP hydrolysis products) with a NaCl gradient elution ranging from 0 to 500 mM
NaCl over 13 min at 0.6 mL/min. Absorption of the uracil moiety was detected at 260 nm. The peak
area of UDP-Gal or UDP-Glc in reactions with inhibitors was compared to a control containing 10%
DMSO. Protein concentrations were calculated from the measured UV-absorbance at 280 nm (Implen
NanoPhotometer N60, Implen GmbH, München, Germany), and the proteins’ individual extinction
coefficients were calculated using the online ProtParam tool (http://web.expasy.org/protparam/) [53].
For the dose-response study and IC50 determination, the same procedure was performed with the
inhibitor concentrations ranging from 7 µM to 500 µM. Corresponding IC50 values were calculated by
using nonlinear regression analysis with variable slope, in GraphPad Prism version 4.00 (GraphPad
Software, San Diego, CA, USA).
4.5. Docking Analysis
Computational docking experiments with AutoDock MGL tools 1.5.6 [54,55] and Schrödinger
Maestro 2018-4 (Schrödinger, LLC, New York, NY, USA, 2018) were performed to identify the compound
binding sites on the protein. UTP- and UTP analog bound-structures of LmUSP and LmUGP (PDB ID:
3OH0, 4M28), respectively, were used to perform the docking experiments. For docking with AutoDock,
crystallization water was retained in the protein structure, and all other hetero molecules were removed
before docking. Protein and compound structures were then prepared in AutoDock, and a grid area
of 126 × 126 × 126 points, covering protein surface inclusive of the active site, was assigned using
AutoGrid, with grid spacing set at 0.4 Å. A Lamarckian genetic algorithm [55] was implemented to dock
the compounds with software settings: the population size of 150, the maximum number of energy
evaluations set to 2,500,000, the maximum number of generations set to 27,000, and the number of
genetic algorithm runs set to 100 [56].
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For docking with Schrödinger Maestro, pre-docking minimization and optimization of the ligand
structures were performed with the ligprep module, using an OPLS_2005 force-field. Protein PDB
structures were prepared in a protein preparation wizard. Crystallization water molecules making at
least two hydrogen bonds with protein atoms were retained, and all other hetero-atoms were removed
from the receptor structures before the docking procedure. Grid maps were generated for both the
proteins, covering protein surface, including the active site. The Glide extra-precision (XP) docking
procedure was followed for docking the ligands to the receptors [57]. The resulting top binding poses
were exported to PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC,
New York, NY, USA) for visualization and image creation.
4.6. Enzyme Kinetics
Michaelis–Menten kinetic parameters were determined for the LmUSP wild-type (WT) and its
mutants, through varying the concentration of Gal-1P at a saturating UTP concentration. Reaction rates
were determined using a commercially available EnzChekTM Pyrophosphate Assay Kit (Molecular
Probes/Life Technologies Corporation, Eugene, OR, USA) which continuously detects the formation
of pyrophosphate during the forward reaction. The assay reaction was run at 25 ◦C in a 100 µL
volume containing 10 mM Tris-HCl pH 8.0, 2 mM MgCl2, 0.12 U inorganic pyrophosphatase, 2 U
purine nucleoside phosphorylase, 200 µM MESG, 1 mM DTT, 0.8 mM UTP, and varying concentrations
of Gal-1P. The enzymatic reactions were carried out in 96-well half-area flat-bottomed microplates
(Greiner Bio-One GmbH, Frickenhausen, Germany), and initiated by the addition of UTP with thorough
mixing. The formation of products was continuously monitored at 360 nm, using a 96-well microplate
reader (Power-WaveTM 340 KC4 system, BioTek® Instruments GmbH, Bad Friedrichshall, Germany).
Initial rates were plotted against Gal-1P concentration, and Km and Vmax values were calculated from
the Michaelis–Menten equation, using nonlinear regression analysis with GraphPad Prism version
4.00 (GraphPad Software, San Diego, CA, USA).
Supplementary Materials: The following are available online, Figure S1: Scaffold and compounds selected
by similarity-based search in the ChemBridge screening compounds database, Figure S2: Nonlinear
regression—sigmoidal dose-response curve for the IC50 determination of compounds #4, #8, #8B, #8D and
#8E bound to LmUSP, Figure S3: Nonlinear regression—sigmoidal dose-response curve for the IC50 determination
of compounds #4, #8, #8B, #8D and #8E bound to LmUGP, Figure S4: Surface representation of LmUGP in
cyanwith the active site colored in blue, Figure S5: Surface representation of LmUSP in green with the active site
colored in blue, Figure S6: Phenylalanine 383 (Wild type) and Tryptophan 330 (introduced by point mutation) are
hypothesized to favor catalytically active conformation via pi- interaction, Table S1: Structure and KD values of all
the hits from the BLI-based fragment binding study.
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